1
|
Bedini A, Boutin JA, Legros C, Zlotos DP, Spadoni G. Industrial and academic approaches to the search for alternative melatonin receptor ligands: An historical survey. J Pineal Res 2024; 76:e12953. [PMID: 38682544 DOI: 10.1111/jpi.12953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2023] [Revised: 03/05/2024] [Accepted: 03/24/2024] [Indexed: 05/01/2024]
Abstract
The search for melatonin receptor agonists formed the main part of melatonin medicinal chemistry programs for the last three decades. In this short review, we summarize the two main aspects of these programs: the development of all the necessary tools to characterize the newly synthesized ligands at the two melatonin receptors MT1 and MT2, and the medicinal chemist's approaches to find chemically diverse ligands at these receptors. Both strategies are described. It turns out that the main source of tools were industrial laboratories, while the medicinal chemistry was mainly carried out in academia. Such complete accounts are interesting, as they delineate the spirits in which the teams were working demonstrating their strength and innovative character. Most of the programs were focused on nonselective agonists and few of them reached the market. In contrast, discovery of MT1-selective agonists and melatonergic antagonists with proven in vivo activity and MT1 or MT2-selectivity is still in its infancy, despite the considerable interest that subtype selective compounds may bring in the domain, as the physiological respective roles of the two subtypes of melatonin receptors, is still poorly understood. Poly-pharmacology applications and multitarget ligands have also been considered.
Collapse
MESH Headings
- Ligands
- Humans
- Animals
- Receptor, Melatonin, MT2/metabolism
- Receptor, Melatonin, MT2/agonists
- Receptor, Melatonin, MT1/metabolism
- Receptor, Melatonin, MT1/agonists
- Receptor, Melatonin, MT1/antagonists & inhibitors
- Receptors, Melatonin/metabolism
- Receptors, Melatonin/agonists
- Melatonin/metabolism
- History, 20th Century
Collapse
Affiliation(s)
- Annalida Bedini
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Urbino, Italy
| | - Jean A Boutin
- Laboratory of Neuroendocrine Endocrine and Germinal Differentiation and Communication (NorDiC), Univ Rouen Normandie, Inserm, NorDiC, Rouen, France
| | | | - Darius P Zlotos
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, The German University in Cairo, New Cairo City, Egypt
| | - Gilberto Spadoni
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino Carlo Bo, Urbino, Italy
| |
Collapse
|
2
|
Feng Y, Jiang X, Liu W, Lu H. The location, physiology, pathology of hippocampus Melatonin MT 2 receptor and MT 2-selective modulators. Eur J Med Chem 2023; 262:115888. [PMID: 37866336 DOI: 10.1016/j.ejmech.2023.115888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2023] [Revised: 10/06/2023] [Accepted: 10/17/2023] [Indexed: 10/24/2023]
Abstract
Melatonin, a neurohormone secreted by the pineal gland and regulated by the suprachiasmatic nucleus (SCN) of the hypothalamus, is synthesized and directly released into the cerebrospinal fluid (CSF) of the third ventricle (3rdv), where it undergoes rapid absorption by surrounding tissues to exert its physiological function. The hippocampus, a vital structure in the limbic system adjacent to the ventricles, plays a pivotal role in emotional response and memory formation. Melatonin MT1 and MT2 receptors are G protein-coupled receptors (GPCRs) that primarily mediate melatonin's receptor-dependent effects. In comparison to the MT1 receptor, the widely expressed MT2 receptor is crucial for mediating melatonin's biological functions within the hippocampus. Specifically, MT2 receptor is implicated in hippocampal synaptic plasticity and memory processes, as well as neurogenesis and axogenesis. Numerous studies have demonstrated the involvement of MT2 receptors in the pathophysiology and pharmacology of Alzheimer's disease, depression, and epilepsy. This review focuses on the anatomical localization of MT2 receptor in the hippocampus, their physiological function in this region, and their signal transduction and pharmacological roles in neurological disorders. Additionally, we conducted a comprehensive review of MT2 receptor ligands used in psychopharmacology and other MT2-selective ligands over recent years. Ultimately, we provide an outlook on future research for selective MT2 receptor drug candidates.
Collapse
Affiliation(s)
- Yueqin Feng
- Department of Ultrasound, the First Affiliated Hospital of China Medical University, Shenyang, PR China
| | - Xiaowen Jiang
- School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, PR China
| | - Wenwu Liu
- School of Pharmaceutical Sciences, Tsinghua University, Beijing, PR China
| | - Hongyuan Lu
- Department of Clinical Pharmacology, China Medical University, Shenyang, PR China.
| |
Collapse
|
3
|
Elisi GM, Scalvini L, Lodola A, Bedini A, Spadoni G, Rivara S. In silico drug discovery of melatonin receptor ligands with therapeutic potential. Expert Opin Drug Discov 2022; 17:343-354. [PMID: 35255751 DOI: 10.1080/17460441.2022.2043846] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION The neurohormone melatonin (N-acetyl-5-methoxytryptamine) regulates circadian rhythms exerting a variety of effects in the central nervous system and in periphery. These activities are mainly mediated by activation of MT1 and MT2 GPCRs. MT1/MT2 agonist compounds are used clinically for insomnia, depression, and circadian rhythm disturbances. AREA COVERED The following review describes the design strategies that have led to the identification of melatonin receptor ligands, guided by in silico approaches and molecular modeling. Initial ligand-based design, mainly relying on pharmacophore modeling and 3D-QSAR, has been flanked by structure-based virtual screening, given the recent availability of MT1 and MT2 crystal structures. Receptor ligands with different activity profiles, agonist/antagonist and subtype-selective compounds, are available. EXPERT OPINION An insight on the pharmacological characterization and therapeutic perspectives for relevant ligands is provided. In silico drug discovery has been instrumental in the design of novel ligands targeting melatonin receptors. Ligand-based approaches has led to the construction of a solid framework defining structure-activity relationships to obtain compounds with a tailored pharmacological profile. Structure-based techniques could integrate previous knowledge and provide compounds with novel chemotypes and pharmacological activity as drug candidates for disease conditions in which melatonin receptor ligands are currently being investigated, including cancer and pain.
Collapse
Affiliation(s)
- Gian Marco Elisi
- Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy
| | - Laura Scalvini
- Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy
| | - Alessio Lodola
- Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy
| | - Annalida Bedini
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino "Carlo Bo", Urbino, Italy
| | - Gilberto Spadoni
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino "Carlo Bo", Urbino, Italy
| | - Silvia Rivara
- Dipartimento di Scienze degli Alimenti e del Farmaco, Università degli Studi di Parma, Parma, Italy
| |
Collapse
|
4
|
Boutin JA, Witt-Enderby PA, Sotriffer C, Zlotos DP. Melatonin receptor ligands: A pharmaco-chemical perspective. J Pineal Res 2020; 69:e12672. [PMID: 32531076 DOI: 10.1111/jpi.12672] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Revised: 05/19/2020] [Accepted: 06/04/2020] [Indexed: 12/14/2022]
Abstract
Melatonin MT1 and MT2 receptor ligands have been vigorously explored for the last 4 decades. Inspection of approximately 80 publications in the field revealed that most melatonergic ligands were structural analogues of melatonin combining three essential features of the parent compound: an aromatic ring bearing a methoxy group and an amide side chain in a relative arrangement similar to that present in melatonin. While several series of MT2 -selective agents-agonists, antagonists, or partial agonists-were reported, the field was lacking MT1 -selective agents. Herein, we describe various approaches toward the development of melatonergic ligands, keeping in mind that most of the molecules/pharmacophores obtained were essentially melatonin copies, even though diverse tri- or tetra-cyclic compounds were explored. In addition to lack of structural diversity, only few studies examined the activity of the reported melatonergic ligands in vivo. Moreover, an extensive pharmacological characterization including biopharmaceutical stability, pharmacokinetic properties, specificity toward other major receptors to name a few remained scarce. For example, many of the antagonists described were not stable in vivo, were not selective for the melatonin receptor subtype of interest, and were not fully characterized from a pharmacological standpoint. Indeed, virtual screening of large compound libraries has led to the recent discovery of potent and selective melatonin receptor agonists and partial agonists of new chemotypes. Having said this, the melatonergic field is still lacking subtype-selective melatonin receptor antagonists "active" in vivo, which are critical to our understanding of melatonin and melatonin receptors' role in basic physiology and disease.
Collapse
MESH Headings
- Animals
- Humans
- Ligands
- Melatonin/chemistry
- Receptor, Melatonin, MT1/agonists
- Receptor, Melatonin, MT1/antagonists & inhibitors
- Receptor, Melatonin, MT1/chemistry
- Receptor, Melatonin, MT2/agonists
- Receptor, Melatonin, MT2/antagonists & inhibitors
- Receptor, Melatonin, MT2/chemistry
Collapse
Affiliation(s)
- Jean A Boutin
- Institut de Recherches Internationales SERVIER, Suresnes, France
| | - Paula A Witt-Enderby
- School of Pharmacy & Graduate School of Pharmaceutical, Administrative and Social Sciences, Duquesne University, Pittsburg, PA, USA
| | - Christoph Sotriffer
- Institute of Pharmacy and Food Chemistry, University of Würzburg, Würzburg, Germany
| | - Darius P Zlotos
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, The German University in Cairo, New Cairo City, Egypt
| |
Collapse
|
5
|
Couhert A, Delagrange P, Caignard DH, Chartier A, Suzenet F, Guillaumet G. Synthesis of 2-arylfuro[3,2-b]pyridines: Effect of the C2-aryl group on melatoninergic activity. Eur J Med Chem 2016; 109:268-75. [DOI: 10.1016/j.ejmech.2016.01.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Revised: 01/07/2016] [Accepted: 01/09/2016] [Indexed: 10/22/2022]
|
6
|
Zhang X, Wang Z, Huang Q, Luo Y, Xie X, Lu W. Design, synthesis, and biological evaluation of a new class of MT2-selective agonists. RSC Adv 2014. [DOI: 10.1039/c4ra03728f] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
In this study, we have designed and synthesized a novel class of chiral 2,3-dihydro-1H-indene derivatives as highly selective MT2 agonists.
Collapse
Affiliation(s)
- Xuan Zhang
- Institute of Drug Discovery and Development
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development
- East China Normal University
- Shanghai 200062, P.R. China
| | - Zhilong Wang
- CAS Key Laboratory of Receptor Research
- National Center for Drug Screening
- Shanghai Institute of Materia Medica Chinese Academy of Sciences
- Shanghai 201203, P.R. China
| | - Qingqing Huang
- Institute of Drug Discovery and Development
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development
- East China Normal University
- Shanghai 200062, P.R. China
| | - Yu Luo
- Institute of Drug Discovery and Development
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development
- East China Normal University
- Shanghai 200062, P.R. China
| | - Xin Xie
- CAS Key Laboratory of Receptor Research
- National Center for Drug Screening
- Shanghai Institute of Materia Medica Chinese Academy of Sciences
- Shanghai 201203, P.R. China
| | - Wei Lu
- Institute of Drug Discovery and Development
- Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development
- East China Normal University
- Shanghai 200062, P.R. China
| |
Collapse
|
7
|
Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA. MT1 and MT2 Melatonin Receptors: Ligands, Models, Oligomers, and Therapeutic Potential. J Med Chem 2013; 57:3161-85. [DOI: 10.1021/jm401343c] [Citation(s) in RCA: 114] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Darius. P. Zlotos
- Department
of Pharmaceutical Chemistry, The German University in Cairo, New Cairo City, 11835 Cairo, Egypt
| | - Ralf Jockers
- Inserm, U1016,
Institut Cochin, Paris, France
- CNRS UMR
8104, Paris, France
- Univ. Paris Descartes, Sorbonne Paris Cite, Paris, France
| | - Erika Cecon
- Department
of Physiology, Institute of Bioscience, University of Sao Paulo, Sao Paulo 05508-090, Brazil
| | - Silvia Rivara
- Dipartimento
di Farmacia, Università degli Studi di Parma, Parco Area
delle Scienze 27/A, 43124 Parma, Italy
| | - Paula A. Witt-Enderby
- Division
of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, 421 Mellon Hall, Pittsburgh, Pennsylvania 15282, United States
| |
Collapse
|
8
|
Pala D, Beuming T, Sherman W, Lodola A, Rivara S, Mor M. Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. J Chem Inf Model 2013; 53:821-35. [PMID: 23541165 DOI: 10.1021/ci4000147] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Developing GPCR homology models for structure-based virtual screening requires the choice of a suitable template and refinement of binding site residues. We explored this systematically for the MT2 melatonin receptor, with the aim to build a receptor homology model that is optimized for the enrichment of active melatoninergic ligands. A set of 12 MT2 melatonin receptor models was built using different GPCR X-ray structural templates and submitted to a virtual screening campaign on a set of compounds composed of 29 known melatonin receptor ligands and 2560 drug-like decoys. To evaluate the effect of including a priori information in receptor models, 12 representative melatonin receptor ligands were placed into the MT2 receptor models in poses consistent with known mutagenesis data and with assessed pharmacophore models. The receptor structures were then adapted to the ligands by induced-fit docking. Most of the 144 ligand-adapted MT2 receptor models showed significant improvements in screening enrichments compared to the unrefined homology models, with some template/refinement combinations giving excellent enrichment factors. The discriminating ability of the models was further tested on the 29 active ligands plus a set of 21 inactive or low-affinity compounds from the same chemical classes. Rotameric states of side chains for some residues, presumed to be involved in the binding process, were correlated with screening effectiveness, suggesting the existence of specific receptor conformations able to recognize active compounds. The top MT2 receptor model was able to identify 24 of 29 active ligands among the first 2% of the screened database. This work provides insights into the use of refined GPCR homology models for virtual screening.
Collapse
Affiliation(s)
- Daniele Pala
- Dipartimento di Farmacia, Università degli Studi di Parma, Parco Area delle Scienze 27/A, I-43124 Parma, Italy
| | | | | | | | | | | |
Collapse
|
9
|
Attia MI, El-Brollosy NR, El-Emam AA, Ng SW, Tiekink ERT. 5-Meth-oxy-2-[(5-meth-oxy-1H-indol-1-yl)carbon-yl]-1H-indole. Acta Crystallogr Sect E Struct Rep Online 2012; 68:o1775. [PMID: 22719553 PMCID: PMC3379355 DOI: 10.1107/s1600536812020399] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2012] [Accepted: 05/07/2012] [Indexed: 11/20/2022]
Abstract
The asymmetric unit of the title compound, C19H16N2O3, comprises three independent molecules (A, B and C). The inversion-related molecule of A is virtually superimposable upon the other two molecules. In each molecule, there is a twist in the link between the approximately syn carbonyl and amine groups [the N—C—C—O torsion angles range from 19.73 (19) to −21.2 (2)°]. Each molecule has a bent shape quantified in terms of the dihedral angle between the indole and indole fused-ring systems [range = 45.69 (5)–47.91 (5)°]. In the crystal, the A and B molecules form dimeric aggregates via ten-membered {⋯HNC2O}2 synthons, while the C molecules self-associate similarly but about a centre of inversion.
Collapse
|
10
|
Bedini A, Lucarini S, Spadoni G, Tarzia G, Scaglione F, Dugnani S, Pannacci M, Lucini V, Carmi C, Pala D, Rivara S, Mor M. Toward the Definition of Stereochemical Requirements for MT2-Selective Antagonists and Partial Agonists by Studying 4-Phenyl-2-propionamidotetralin Derivatives. J Med Chem 2011; 54:8362-72. [DOI: 10.1021/jm200790v] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Annalida Bedini
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, I-61029 Urbino, Italy
| | - Simone Lucarini
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, I-61029 Urbino, Italy
| | - Gilberto Spadoni
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, I-61029 Urbino, Italy
| | - Giorgio Tarzia
- Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, I-61029 Urbino, Italy
| | - Francesco Scaglione
- Dipartimento di Farmacologia,
Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, I-20129 Milano,
Italy
| | - Silvana Dugnani
- Dipartimento di Farmacologia,
Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, I-20129 Milano,
Italy
| | - Marilou Pannacci
- Dipartimento di Farmacologia,
Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, I-20129 Milano,
Italy
| | - Valeria Lucini
- Dipartimento di Farmacologia,
Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, I-20129 Milano,
Italy
| | - Caterina Carmi
- Dipartimento Farmaceutico, Università degli Studi di Parma, Viale G. P.
Usberti 27/A Campus Universitario, I-43124 Parma, Italy
| | - Daniele Pala
- Dipartimento Farmaceutico, Università degli Studi di Parma, Viale G. P.
Usberti 27/A Campus Universitario, I-43124 Parma, Italy
| | - Silvia Rivara
- Dipartimento Farmaceutico, Università degli Studi di Parma, Viale G. P.
Usberti 27/A Campus Universitario, I-43124 Parma, Italy
| | - Marco Mor
- Dipartimento Farmaceutico, Università degli Studi di Parma, Viale G. P.
Usberti 27/A Campus Universitario, I-43124 Parma, Italy
| |
Collapse
|
11
|
Markl C, Clafshenkel WP, Attia MI, Sethi S, Witt-Enderby PA, Zlotos DP. N-Acetyl-5-arylalkoxytryptamine Analogs: Probing the Melatonin Receptors for MT1-Selectivity. Arch Pharm (Weinheim) 2011; 344:666-74. [DOI: 10.1002/ardp.201100125] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2011] [Revised: 05/11/2011] [Accepted: 05/13/2011] [Indexed: 11/07/2022]
|
12
|
Mésangeau C, Fraise M, Delagrange P, Caignard DH, Boutin JA, Berthelot P, Yous S. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands. Eur J Med Chem 2011; 46:1835-40. [DOI: 10.1016/j.ejmech.2011.02.044] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2010] [Revised: 02/16/2011] [Accepted: 02/17/2011] [Indexed: 12/15/2022]
|
13
|
Heckman D, Attia MI, Behnam MAM, Mohsen AMY, Markl C, Julius J, Sethi S, Witt-Enderby PA, Zlotos DP. 2-[(1,3-Dihydro-2H-isoindol-2-yl)methyl]melatonin – a novel MT2-selective melatonin receptor antagonist. MEDCHEMCOMM 2011. [DOI: 10.1039/c1md00149c] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
14
|
Mésangeau C, Pérès B, Descamps-François C, Chavatte P, Audinot V, Coumailleau S, Boutin JA, Delagrange P, Bennejean C, Renard P, Caignard DH, Berthelot P, Yous S. Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT1 melatoninergic ligands. Bioorg Med Chem 2010; 18:3426-36. [DOI: 10.1016/j.bmc.2010.04.008] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2010] [Revised: 03/31/2010] [Accepted: 04/01/2010] [Indexed: 12/15/2022]
|
15
|
Yoo K, Kim H, Yun J. Asymmetric Synthesis of 1,1-Diarylalkyl Units by a Copper Hydride Catalyzed Reduction: Differentiation Between Two Similar Aryl Substituents. Chemistry 2009; 15:11134-8. [DOI: 10.1002/chem.200901262] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
16
|
Synthesis and pharmacological evaluation of 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues as novel melatoninergic ligands. Bioorg Med Chem 2009; 17:4583-94. [DOI: 10.1016/j.bmc.2009.04.068] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2008] [Revised: 04/27/2009] [Accepted: 04/30/2009] [Indexed: 11/23/2022]
|
17
|
Durieux S, Chanu A, Bochu C, Audinot V, Coumailleau S, Boutin JA, Delagrange P, Caignard DH, Bennejean C, Renard P, Lesieur D, Berthelot P, Yous S. Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II. Bioorg Med Chem 2009; 17:2963-74. [DOI: 10.1016/j.bmc.2009.03.023] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2009] [Revised: 03/05/2009] [Accepted: 03/11/2009] [Indexed: 12/15/2022]
|
18
|
Zlotos DP, Attia MI, Julius J, Sethi S, Witt-Enderby PA. 2-[(2,3-Dihydro-1H-indol-1-yl)methyl]melatonin Analogues: A Novel Class of MT2-Selective Melatonin Receptor Antagonists. J Med Chem 2009; 52:826-33. [DOI: 10.1021/jm800974d] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Darius P. Zlotos
- Institute of Pharmacy and Food Chemistry, Pharmaceutical Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany, and Division of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, 421 Mellon Hall, Pittsburgh, Pennsylvania 15282
| | - Mohamed I. Attia
- Institute of Pharmacy and Food Chemistry, Pharmaceutical Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany, and Division of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, 421 Mellon Hall, Pittsburgh, Pennsylvania 15282
| | - Justin Julius
- Institute of Pharmacy and Food Chemistry, Pharmaceutical Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany, and Division of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, 421 Mellon Hall, Pittsburgh, Pennsylvania 15282
| | - Shalini Sethi
- Institute of Pharmacy and Food Chemistry, Pharmaceutical Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany, and Division of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, 421 Mellon Hall, Pittsburgh, Pennsylvania 15282
| | - Paula A. Witt-Enderby
- Institute of Pharmacy and Food Chemistry, Pharmaceutical Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany, and Division of Pharmaceutical Sciences, School of Pharmacy, Duquesne University, 421 Mellon Hall, Pittsburgh, Pennsylvania 15282
| |
Collapse
|
19
|
Fischer TW, Slominski A, Zmijewski MA, Reiter RJ, Paus R. Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair. Exp Dermatol 2008; 17:713-30. [DOI: 10.1111/j.1600-0625.2008.00767.x] [Citation(s) in RCA: 116] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
20
|
Synthesis of 3-phenylnaphthalenic derivatives as new selective MT2 melatoninergic ligands. Bioorg Med Chem 2008; 16:8339-48. [DOI: 10.1016/j.bmc.2008.08.052] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2008] [Revised: 08/18/2008] [Accepted: 08/22/2008] [Indexed: 12/15/2022]
|
21
|
Antioxidative effect of melatonin on DNA and erythrocytes against free-radical-induced oxidation. Chem Phys Lipids 2008; 151:77-84. [DOI: 10.1016/j.chemphyslip.2007.10.002] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2007] [Revised: 09/26/2007] [Accepted: 10/02/2007] [Indexed: 12/15/2022]
|
22
|
Rivara S, Lodola A, Mor M, Bedini A, Spadoni G, Lucini V, Pannacci M, Fraschini F, Scaglione F, Sanchez RO, Gobbi G, Tarzia G. N-(Substituted-anilinoethyl)amides: Design, Synthesis, and Pharmacological Characterization of a New Class of Melatonin Receptor Ligands. J Med Chem 2007; 50:6618-26. [DOI: 10.1021/jm700957j] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Silvia Rivara
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| | - Alessio Lodola
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| | - Marco Mor
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| | - Annalida Bedini
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| | - Gilberto Spadoni
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| | - Valeria Lucini
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| | - Marilou Pannacci
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| | - Franco Fraschini
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| | - Francesco Scaglione
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| | - Rafael Ochoa Sanchez
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| | - Gabriella Gobbi
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| | - Giorgio Tarzia
- Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, Campus Universitario, 43100 Parma, Italy, Istituto di Chimica Farmaceutica e Tossicologica, Universitá degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, 61029 Urbino, Italy, Dipartimento di Farmacologia, Chemioterapia e Tossicologia Medica, Università degli Studi di Milano, Via Vanvitelli 32, 20129 Milano, Italy, Department of Psychiatry, McGill University, Montréal, QC, Canada H1N 3V2, and Department of
| |
Collapse
|
23
|
Wu PW, Cheng YM, Hsieh WT, Wang YH, Wei CY, Chou PT. 7-Azamelatonin: Efficient Synthetic Routes, Excited-State Double Proton Transfer Properties and Biomedical Implications. ChemMedChem 2007; 2:1071-5. [PMID: 17477342 DOI: 10.1002/cmdc.200700043] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
On the basis of a seven-step synthetic route, the total synthesis of 7-azamelatonin, an analogue of melatonin, has been achieved with an overall yield of approximately 9.2%. In aqueous solution, 7-azamelatonin exhibits a unique excited-state double proton transfer (ESDPT) property, resulting in dual emission bands (405 and 560 nm). The ESDPT property makes 7-azamelatonin superb as a potential molecular probe for future bioapplication and for pharmacological research.
Collapse
Affiliation(s)
- Pei-Wen Wu
- Department of Chemistry, National Taiwan University, Taipei, 106, Taiwan, ROC
| | | | | | | | | | | |
Collapse
|